Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Nea Ionia – page 86

1 034 clinical trials in Nea Ionia, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Nea Ionia at a glance
1 034
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 034 trials in Nea Ionia

Open in trial search

Study on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Ulm AöR

Study on Golexanolone for Patients with Primary Biliary Cholangitis Experiencing Fatigue and Cognitive Dysfunction

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Golexanolone
  • Sponsor:Umecrine Cognition AB

Sepsis

Not recruiting

Study on Emapalumab for Patients with Sepsis Linked to Interferon-Gamma

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Emapalumab
  • Sponsor:Hellenic Institute For The Study Of Sepsis

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effects of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Retifanlimab
  • Sponsor:Incyte Biosciences International S.a.r.l.

Pemphigoid

Not recruiting

Study on Long-term Safety and Effects of Efgartigimod PH20 SC for Adults with Bullous Pemphigoid

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Cardiac failure+4

Not recruiting

Study on the Effects of CDR132L in Patients with Reduced Heart Function After a Heart Attack

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:CDR132L
  • Sponsor:Cardior Pharmaceuticals GmbH

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with Advanced Unresectable Urothelial Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Gilead Sciences Inc.

Study on the Risk of Tumor Lysis Syndrome in Adults with Untreated Chronic Lymphocytic Leukemia Using Venetoclax, Obinutuzumab, or Acalabrutinib

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Other cities in Greece

The busiest research cities in the country

All 47 cities in Greece

Clinical research in Nea Ionia

What the registry says about research in the country

01 Cardiovascular Disease Management

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluate new therapeutic approaches for reducing cardiovascular risks.

  • Cardiovascular event prevention
  • Lipoprotein management
  • Heart disease treatments

Advanced trials exploring novel compounds for improved patient outcomes.

02 Atrial Fibrillation Treatment

Comprehensive studies examining various approaches to manage atrial fibrillation, including new medications for stroke prevention and cardiac rhythm control.

  • Stroke prevention therapies
  • Cardioversion treatments
  • Anticoagulation management

Multiple therapeutic options being evaluated for different patient populations.

03 Heart Failure Research

Investigation of innovative treatments for chronic heart failure, focusing on patients with reduced ejection fraction and those with kidney complications.

  • Medication effectiveness studies
  • Combined therapy approaches
  • Cardiovascular outcomes

Evaluating new therapeutic combinations to improve patient survival and quality of life.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.